Literature DB >> 23151413

MRI perfusion in determining pseudoprogression in patients with glioblastoma.

Robert J Young1, Ajay Gupta, Akash D Shah, Jerome J Graber, Timothy A Chan, Zhigang Zhang, Weiji Shi, Kathryn Beal, Antonio M Omuro.   

Abstract

We examine the role of dynamic susceptibility contrast (DSC) magnetic resonance imaging (MRI) perfusion in differentiating pseudoprogression from progression in 20 consecutive patients with treated glioblastoma. MRI perfusion was performed, and relative cerebral blood volume (rCBV), relative peak height (rPH), and percent signal recovery (PSR) were measured. Pseudoprogression demonstrated lower median rCBV (P=.009) and rPH (P<.001), and higher PSR (P=.039) than progression. DSC MRI perfusion successfully identified pseudoprogression in patients who did not require a change in treatment despite radiographic worsening following chemoradiotherapy.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Year:  2012        PMID： 23151413      PMCID： PMC4755513          DOI： 10.1016/j.clinimag.2012.02.016

Source DB:  PubMed          Journal:  Clin Imaging        ISSN： 0899-7071            Impact factor:   1.605


  48 in total

1.  Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study.

Authors:  Stephan G Wetzel; Soonmee Cha; Glyn Johnson; Peter Lee; Meng Law; David L Kasow; Sean D Pierce; Xiaonan Xue
Journal:  Radiology       Date:  2002-09       Impact factor: 11.105

Review 2.  Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.

Authors:  M C Y de Wit; H G de Bruin; W Eijkenboom; P A E Sillevis Smitt; M J van den Bent
Journal:  Neurology       Date:  2004-08-10       Impact factor: 9.910

3.  Response criteria for phase II studies of supratentorial malignant glioma.

Authors:  D R Macdonald; T L Cascino; S C Schold; J G Cairncross
Journal:  J Clin Oncol       Date:  1990-07       Impact factor: 44.544

4.  The risk of cerebral radionecrosis in relation to dose, time and fractionation. A follow-up study.

Authors:  J E Marks; J Wong
Journal:  Prog Exp Tumor Res       Date:  1985

5.  Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.

Authors:  James R Perry; Karl Bélanger; Warren P Mason; Dorcas Fulton; Petr Kavan; Jacob Easaw; Claude Shields; Sarah Kirby; David R Macdonald; David D Eisenstat; Brian Thiessen; Peter Forsyth; Jean-François Pouliot
Journal:  J Clin Oncol       Date:  2010-03-22       Impact factor: 44.544

6.  Correlations between magnetic resonance spectroscopy and image-guided histopathology, with special attention to radiation necrosis.

Authors:  Jack P Rock; David Hearshen; Lisa Scarpace; David Croteau; Jorge Gutierrez; James L Fisher; Mark L Rosenblum; Tom Mikkelsen
Journal:  Neurosurgery       Date:  2002-10       Impact factor: 4.654

7.  Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury.

Authors:  Patrick A Hein; Clifford J Eskey; Jeffrey F Dunn; Eugen B Hug
Journal:  AJNR Am J Neuroradiol       Date:  2004-02       Impact factor: 3.825

Review 8.  Dynamic magnetic resonance perfusion imaging of brain tumors.

Authors:  Diego J Covarrubias; Bruce R Rosen; Michael H Lev
Journal:  Oncologist       Date:  2004

9.  Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial.

Authors:  W Roa; P M A Brasher; G Bauman; M Anthes; E Bruera; A Chan; B Fisher; D Fulton; S Gulavita; C Hao; S Husain; A Murtha; K Petruk; D Stewart; P Tai; R Urtasun; J G Cairncross; P Forsyth
Journal:  J Clin Oncol       Date:  2004-03-29       Impact factor: 44.544

10.  Methionine PET for follow-up of radiation therapy of primary lymphoma of the brain.

Authors:  T Ogawa; I Kanno; J Hatazawa; A Inugami; H Fujita; E Shimosegawa; M Murakami; T Okudera; K Uemura; N Yasui
Journal:  Radiographics       Date:  1994-01       Impact factor: 5.333
View more
  57 in total

Review 1.  Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma.

Authors:  Mark S Shiroishi; Jerrold L Boxerman; Whitney B Pope
Journal:  Neuro Oncol       Date:  2015-09-12       Impact factor: 12.300

2.  ASFNR recommendations for clinical performance of MR dynamic susceptibility contrast perfusion imaging of the brain.

Authors:  K Welker; J Boxerman; A Kalnin; T Kaufmann; M Shiroishi; M Wintermark
Journal:  AJNR Am J Neuroradiol       Date:  2015-04-23       Impact factor: 3.825

3.  DCE-MRI perfusion predicts pseudoprogression in metastatic melanoma treated with immunotherapy.

Authors:  Yoshie Umemura; Diane Wang; Kyung K Peck; Jessica Flynn; Zhigang Zhang; Robin Fatovic; Erik S Anderson; Kathryn Beal; Alexander N Shoushtari; Thomas Kaley; Robert J Young
Journal:  J Neurooncol       Date:  2019-12-24       Impact factor: 4.130

Review 4.  Accuracy of percentage of signal intensity recovery and relative cerebral blood volume derived from dynamic susceptibility-weighted, contrast-enhanced MRI in the preoperative diagnosis of cerebral tumours.

Authors:  Ananya Chakravorty; Timothy Steel; Joga Chaganti
Journal:  Neuroradiol J       Date:  2015-10-16

Review 5.  MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis.

Authors:  Praneil Patel; Hediyeh Baradaran; Diana Delgado; Gulce Askin; Paul Christos; Apostolos John Tsiouris; Ajay Gupta
Journal:  Neuro Oncol       Date:  2016-08-08       Impact factor: 12.300

6.  Characterization of pseudoprogression in patients with glioblastoma: is histology the gold standard?

Authors:  Isaac Melguizo-Gavilanes; Janet M Bruner; Nandita Guha-Thakurta; Kenneth R Hess; Vinay K Puduvalli
Journal:  J Neurooncol       Date:  2015-04-18       Impact factor: 4.130

Review 7.  Response Assessment in Neuro-Oncology Criteria for Gliomas: Practical Approach Using Conventional and Advanced Techniques.

Authors:  D J Leao; P G Craig; L F Godoy; C C Leite; B Policeni
Journal:  AJNR Am J Neuroradiol       Date:  2019-12-19       Impact factor: 3.825

8.  Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question.

Authors:  Morad Nasseri; Seymur Gahramanov; Joao Prola Netto; Rongwei Fu; Leslie L Muldoon; Csanad Varallyay; Bronwyn E Hamilton; Edward A Neuwelt
Journal:  Neuro Oncol       Date:  2014-02-11       Impact factor: 12.300

9.  Vascular Reactivity Maps in Patients with Gliomas Using Breath-Holding BOLD fMRI.

Authors:  Amir Iranmahboob; Kyung K Peck; Nicole P Brennan; Sasan Karimi; Ryan Fisicaro; Bob Hou; Andrei I Holodny
Journal:  J Neuroimaging       Date:  2016 Mar-Apr       Impact factor: 2.486

10.  Differentiating pseudoprogression from true progression: analysis of radiographic, biologic, and clinical clues in GBM.

Authors:  Lindsay S Rowe; John A Butman; Megan Mackey; Joanna H Shih; Theresa Cooley-Zgela; Holly Ning; Mark R Gilbert; DeeDee K Smart; Kevin Camphausen; Andra V Krauze
Journal:  J Neurooncol       Date:  2018-05-16       Impact factor: 4.130
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.